A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Antimicrobial Peptide PL-18 Vaginal Suppositories in Healthy Adult Subjects
Latest Information Update: 15 Dec 2023
Price :
$35 *
At a glance
- Drugs PL 18 (Primary)
- Indications Bacterial vaginosis; Mycoses; Vaginitis
- Focus Adverse reactions; First in man
- Sponsors Jiangsu ProteLight Pharmaceutical and Biotechnology
- 04 Dec 2023 Planned End Date changed from 1 Feb 2023 to 1 Mar 2024.
- 13 Oct 2022 Status changed from not yet recruiting to recruiting.
- 28 Apr 2022 New trial record